CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
MGTA-145 +1 moredrug
Likely dose
Plerixafor 0.24 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04552743
NCT04552743Phase 2Completed
CompareCT.gov

Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma

Surbhi Sidana, MD·interventional·Posted Sep 17, 2020·Updated Sep 10, 2022

In Brief

A Phase 2 clinical trial evaluating MGTA-145 and Plerixafor for Multiple Myeloma. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This study evaluates a new drug MGTA-145 in combination with plerixafor (Mozobil) to mobilize stem cells into the peripheral blood for collection by apheresis. The stem cells will be used for autologous stem cell transplant for treatment of multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedSep 17, 2020
Enrollment StartOct 5, 2020
Primary CompletionJul 22, 2021
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.8 years ago

Interventions

MGTA-145drug

A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.

Plerixafordrug

An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).